MAB2052
Anti-Disialoganglioside GD2 Antibody, clone 14G2a
clone 14.2Ga, Chemicon®, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
14.2Ga, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
isotype
IgG2a
shipped in
wet ice
target post-translational modification
unmodified
Related Categories
Specificity
Reacts specifically with human GD2 ganglioside.
Application
Anti-Disialoganglioside GD2 Antibody, clone 14G2a detects level of Disialoganglioside GD2 & has been published & validated for use in FC, IF, IH.
Immunohistochemistry (frozen tissue sections)(Cheresh et al., 1986)
Immunofluorescence of cells in culture
Flow cytometry: 1-2 μg per 10E6 cells
Cytotoxicity for GD2 positive cells (Mujoo et al., 1987, 1989)
Optimal working dilutions must be determined by end user.
Immunofluorescence of cells in culture
Flow cytometry: 1-2 μg per 10E6 cells
Cytotoxicity for GD2 positive cells (Mujoo et al., 1987, 1989)
Optimal working dilutions must be determined by end user.
Physical form
Cell culture supernatant in 0.02M PB, pH 7.6, 0.25M NaCl containing 0.1% Sodium Azide
Format: Purified
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Antonella Brizzolara et al.
Molecules (Basel, Switzerland), 25(22) (2020-11-14)
Despite significant improvement of neuroblastoma (NB) patients' survival due to recent treatment advancements in recent years, NB is still associated with high mortality rate. In search of novel strategies to increase NB's susceptibility to pharmacological treatments, we investigated the in
Martin V Kolev et al.
Journal of immunology (Baltimore, Md. : 1950), 184(11), 6035-6042 (2010-04-28)
Tumor cells escape clearance by complement by abundantly expressing CD59 and other membrane complement regulators. Recently, we designed a peptide derived from the neural-restrictive silencer factor (REST), REST68, which we showed to inhibit expression of CD59 in tumors lacking the
Patrizia Garbati et al.
Biomedicines, 8(11) (2020-11-07)
To overcome the lack of effective pharmacological treatments for high-risk neuroblastoma (HR-NB), the development of novel in vitro and in vivo models that better recapitulate the disease is required. Here, we used an in vitro multiclonal cell model encompassing NB
Hideki Yoshida et al.
Scientific reports, 10(1), 1199-1199 (2020-01-29)
β-1,4-N-Acetyl-Galactosaminyltransferase 1 (B4GALNT1) encodes the key enzyme B4GALNT1 to generate gangliosides GM2/GD2. GM2/GD2 gangliosides are surface glycolipids mainly found on brain neurons as well as peripheral nerves and skin melanocytes and are reported to exacerbate the malignant potential of melanomas.
Patrizia Garbati et al.
International journal of molecular sciences, 22(13) (2021-07-03)
High-risk neuroblastoma (HR-NB) still remains the most dangerous tumor in early childhood. For this reason, the identification of new therapeutic approaches is of fundamental importance. Recently, we combined the conventional pharmacological approach to NB, represented by cisplatin, with fendiline hydrochloride
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service